These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 11554011)
1. Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease. McNaught KS; Lee M; Hyun DH; Jenner P Adv Neurol; 2001; 86():73-82. PubMed ID: 11554011 [No Abstract] [Full Text] [Related]
2. Lewy bodies in Parkinson's disease: protectors or perpetrators? Harrower TP; Michell AW; Barker RA Exp Neurol; 2005 Sep; 195(1):1-6. PubMed ID: 16023637 [No Abstract] [Full Text] [Related]
3. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Lotharius J; Brundin P Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550 [No Abstract] [Full Text] [Related]
4. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
5. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. Sidhu A; Wersinger C; Vernier P FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042 [TBL] [Abstract][Full Text] [Related]
6. [Free radicals and ailing proteins--the culprits behind Parkinson disease?]. Smith R; Lotharius J; Brundin P Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402 [TBL] [Abstract][Full Text] [Related]
7. Glia: initiators and progressors of pathology in Parkinson's disease. Halliday GM; Stevens CH Mov Disord; 2011 Jan; 26(1):6-17. PubMed ID: 21322014 [TBL] [Abstract][Full Text] [Related]
8. Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease. Mochizuki A; Komatsuzaki Y; Shoji S Acta Neuropathol; 2002 Nov; 104(5):534-7. PubMed ID: 12410401 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Watanabe Y; Himeda T; Araki T Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202 [TBL] [Abstract][Full Text] [Related]
15. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of nigral cell death in Parkinson's disease. Przedborski S Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625 [TBL] [Abstract][Full Text] [Related]
17. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Huisman E; Uylings HB; Hoogland PV Mov Disord; 2008 Jul; 23(10):1407-13. PubMed ID: 18581481 [TBL] [Abstract][Full Text] [Related]
19. Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease. Wakabayashi K; Mori F; Oyama Y; Kurihara A; Kamada M; Yoshimoto M; Takahashi H Acta Neuropathol; 2003 Feb; 105(2):189-92. PubMed ID: 12536231 [TBL] [Abstract][Full Text] [Related]
20. Controlling the mass action of alpha-synuclein in Parkinson's disease. Kim C; Lee SJ J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]